Compare QCLS & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QCLS | BTAI |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1M | 27.7M |
| IPO Year | N/A | 2018 |
| Metric | QCLS | BTAI |
|---|---|---|
| Price | $2.75 | $0.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 182.2K | ★ 1.4M |
| Earning Date | 04-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.63 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $197.82 |
| Revenue Next Year | N/A | $910.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $0.74 |
| 52 Week High | $8.17 | $8.08 |
| Indicator | QCLS | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 34.79 | 41.33 |
| Support Level | $2.53 | $0.74 |
| Resistance Level | $3.90 | $1.41 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 24.47 | 35.48 |
Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.